Cargando…

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate

BACKGROUND: The radiolanthanide (161)Tb has, in recent years, attracted increasing interest due to its favorable characteristics for medical application. (161)Tb exhibits similar properties to the widely-used therapeutic radionuclide (177)Lu. In contrast to (177)Lu, (161)Tb yields a significant numb...

Descripción completa

Detalles Bibliográficos
Autores principales: Haller, Stephanie, Pellegrini, Giovanni, Vermeulen, Christiaan, van der Meulen, Nicholas P., Köster, Ulli, Bernhardt, Peter, Schibli, Roger, Müller, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747949/
https://www.ncbi.nlm.nih.gov/pubmed/26860295
http://dx.doi.org/10.1186/s13550-016-0171-1
_version_ 1782415033901252608
author Haller, Stephanie
Pellegrini, Giovanni
Vermeulen, Christiaan
van der Meulen, Nicholas P.
Köster, Ulli
Bernhardt, Peter
Schibli, Roger
Müller, Cristina
author_facet Haller, Stephanie
Pellegrini, Giovanni
Vermeulen, Christiaan
van der Meulen, Nicholas P.
Köster, Ulli
Bernhardt, Peter
Schibli, Roger
Müller, Cristina
author_sort Haller, Stephanie
collection PubMed
description BACKGROUND: The radiolanthanide (161)Tb has, in recent years, attracted increasing interest due to its favorable characteristics for medical application. (161)Tb exhibits similar properties to the widely-used therapeutic radionuclide (177)Lu. In contrast to (177)Lu, (161)Tb yields a significant number of short-ranging Auger/conversion electrons (≤50 keV) during its decay process. (161)Tb has been shown to be more effective for tumor therapy than (177)Lu if applied using the same activity. The purpose of this study was to investigate long-term damage to the kidneys after application of (161)Tb-folate and compare it to the renal effects caused by (177)Lu-folate. METHODS: Renal side effects were investigated in nude mice after the application of different activities of (161)Tb-folate (10, 20, and 30 MBq per mouse) over a period of 8 months. Renal function was monitored by the determination of (99m)Tc-DMSA uptake in the kidneys and by measuring blood urea nitrogen and creatinine levels in the plasma. Histopathological analysis was performed by scoring of the tissue damage observed in HE-stained kidney sections from euthanized mice. RESULTS: Due to the co-emitted Auger/conversion electrons, the mean absorbed renal dose of (161)Tb-folate (3.0 Gy/MBq) was about 24 % higher than that of (177)Lu-folate (2.3 Gy/MBq). After application of (161)Tb-folate, kidney function was reduced in a dose- and time-dependent manner, as indicated by the decreased renal uptake of (99m)Tc-DMSA and the increased levels of blood urea nitrogen and creatinine. Similar results were obtained when (177)Lu-folate was applied at the same activity. Histopathological investigations confirmed comparable renal cortical damage after application of the same activities of (161)Tb-folate and (177)Lu-folate. This was characterized by collapsed tubules and enlarged glomeruli with fibrin deposition in moderately injured kidneys and glomerulosclerosis in severely damaged kidneys. CONCLUSIONS: Tb-folate induced dose-dependent radionephropathy over time, but did not result in more severe damage than (177)Lu-folate when applied at the same activity. These data are an indication that Auger/conversion electrons do not exacerbate overall renal damage after application with (161)Tb-folate as compared to (177)Lu-folate, even though they result in an increased dose deposition in the renal tissue. Global toxicity affecting other tissues than kidneys remains to be investigated after (161)Tb-based therapy, however.
format Online
Article
Text
id pubmed-4747949
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47479492016-02-19 Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate Haller, Stephanie Pellegrini, Giovanni Vermeulen, Christiaan van der Meulen, Nicholas P. Köster, Ulli Bernhardt, Peter Schibli, Roger Müller, Cristina EJNMMI Res Original Research BACKGROUND: The radiolanthanide (161)Tb has, in recent years, attracted increasing interest due to its favorable characteristics for medical application. (161)Tb exhibits similar properties to the widely-used therapeutic radionuclide (177)Lu. In contrast to (177)Lu, (161)Tb yields a significant number of short-ranging Auger/conversion electrons (≤50 keV) during its decay process. (161)Tb has been shown to be more effective for tumor therapy than (177)Lu if applied using the same activity. The purpose of this study was to investigate long-term damage to the kidneys after application of (161)Tb-folate and compare it to the renal effects caused by (177)Lu-folate. METHODS: Renal side effects were investigated in nude mice after the application of different activities of (161)Tb-folate (10, 20, and 30 MBq per mouse) over a period of 8 months. Renal function was monitored by the determination of (99m)Tc-DMSA uptake in the kidneys and by measuring blood urea nitrogen and creatinine levels in the plasma. Histopathological analysis was performed by scoring of the tissue damage observed in HE-stained kidney sections from euthanized mice. RESULTS: Due to the co-emitted Auger/conversion electrons, the mean absorbed renal dose of (161)Tb-folate (3.0 Gy/MBq) was about 24 % higher than that of (177)Lu-folate (2.3 Gy/MBq). After application of (161)Tb-folate, kidney function was reduced in a dose- and time-dependent manner, as indicated by the decreased renal uptake of (99m)Tc-DMSA and the increased levels of blood urea nitrogen and creatinine. Similar results were obtained when (177)Lu-folate was applied at the same activity. Histopathological investigations confirmed comparable renal cortical damage after application of the same activities of (161)Tb-folate and (177)Lu-folate. This was characterized by collapsed tubules and enlarged glomeruli with fibrin deposition in moderately injured kidneys and glomerulosclerosis in severely damaged kidneys. CONCLUSIONS: Tb-folate induced dose-dependent radionephropathy over time, but did not result in more severe damage than (177)Lu-folate when applied at the same activity. These data are an indication that Auger/conversion electrons do not exacerbate overall renal damage after application with (161)Tb-folate as compared to (177)Lu-folate, even though they result in an increased dose deposition in the renal tissue. Global toxicity affecting other tissues than kidneys remains to be investigated after (161)Tb-based therapy, however. Springer Berlin Heidelberg 2016-02-09 /pmc/articles/PMC4747949/ /pubmed/26860295 http://dx.doi.org/10.1186/s13550-016-0171-1 Text en © Haller et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Haller, Stephanie
Pellegrini, Giovanni
Vermeulen, Christiaan
van der Meulen, Nicholas P.
Köster, Ulli
Bernhardt, Peter
Schibli, Roger
Müller, Cristina
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
title Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
title_full Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
title_fullStr Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
title_full_unstemmed Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
title_short Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
title_sort contribution of auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)tb-folate and (177)lu-folate
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747949/
https://www.ncbi.nlm.nih.gov/pubmed/26860295
http://dx.doi.org/10.1186/s13550-016-0171-1
work_keys_str_mv AT hallerstephanie contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate
AT pellegrinigiovanni contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate
AT vermeulenchristiaan contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate
AT vandermeulennicholasp contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate
AT kosterulli contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate
AT bernhardtpeter contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate
AT schibliroger contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate
AT mullercristina contributionofaugerconversionelectronstorenalsideeffectsafterradionuclidetherapypreclinicalcomparisonof161tbfolateand177lufolate